title: [Rationale and methods for high dose chemotherapy in oncology].
abstract: Waiting for a new, highly effective cytotoxic drugs it is necessary to improve antineoplastic treatment using presently existing drugs and methods. Chemosensitive tumors should be treated with intensive, short-lasting courses of the induction as well as of the adjuvant chemotherapy. Chemotherapy delay, dose reduction, unproper therapy regimen increases risk of the development of drug-resistance and treatment failure. Autologous hemopoietic cell transplantation allows cytostatics dose escalation (high-dose chemotherapy, HDCT) with an acceptable non-hematological toxicity. HDCT with autologous peripheral blood stem cell transplantation (auto-PBSCT) is increasingly used. Auto-PBSCT has the same efficacy as autologous bone marrow transplantation (ABMT), but it is a safer procedure, allows more rapid hemopoietic recovery and shorter hospitalization.
authors.affiliation: Kliniki Hematologii Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie. alekskot@endo.cm-uj.krakow.pl
authors.forename: A B
authors.initials: AB
authors.lastname: Skotnicki
authors.forename: M
authors.initials: M
authors.lastname: Machaczka
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D004351:Drug Resistance; D006402:Hematologic Diseases / Q000139:chemically induced / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007902:Length of Stay; D008495:Medical Oncology / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*